Aveanna Healthcare Holdings, Inc. (AVAH)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Research Workspace
Put AVAH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 29% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskAveanna Healthcare must maintain strong revenue growth to justify its price. The company raised its full-year revenue guidance to over $2.68 billion. Q2 revenue was $670.5 million, a 13.7% increase year-over-year. It trades at 19× P/E, below the peer median of 23×. The market is pricing in more growth than expected, making it look expensive. If Aveanna cuts guidance after raising it, that would hurt credibility. The read shows peer multiples imply a price about 29% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. AVAH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering AVAH (as of Sep 2026).
Based on 8 Wall Street analysts offering 12-month price targets for AVAH in the last 4 months.
Continue this research
Compare AVAH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AVAH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put AVAH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Secondary offering may dilute shareholder value and affect capital structure.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $13.58
The last 12 months of price, then the range of analyst 12-month targets from today’s $13.58.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Increase revenue guidance for 2026
Earnings beat supports revenue growth expectations.

Advances: Increase revenue guidance for 2026
Strong revenue performance supports 2026 growth guidance.

Q2 earnings report indicates strong revenue and EBITDA growth.

Advances: Increase revenue guidance for 2026
Raising outlook confirms growth trajectory post-acquisition.
Advances: Increase revenue guidance for 2026
Increased price target reflects strong performance.
Advances: Increase Adjusted EBITDA guidance for 2026
Earnings beat supports adjusted EBITDA growth.
Advances: Increase revenue guidance for 2026
Strong revenue growth aligns with growth objectives.